RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group

C. J A Punt, M. J A De Jonge, S. Monfardini, G. Daugaard, W. Fiedler, B. Baron, D. Lacombe, P. Fumoleau

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group'. Together they form a unique fingerprint.

Medicine & Life Sciences